Bioventus INC Form 4 insider transactions

Director John Bartholdson exercised restricted stock units and received a new grant of equity in Bioventus Inc.

Director Martin Sutter acquired 32,282 shares of Bioventus Class A Common Stock via RSU vesting and was granted 25,146 new RSUs.

Director Susan Stalnecker acquired 32,282 shares of Bioventus Class A Common Stock via RSU vesting and was granted 25,146 new RSUs.

Director Guy Nohra acquired 32,282 shares of Bioventus Class A Common Stock through RSU vesting and was granted 25,146 new RSUs.

Director Guido Neels acquired 32,282 shares of Bioventus Class A common stock through RSU vesting and was granted 25,146 new RSUs.

Director Michelle McMurry-Heath acquired 32,282 shares of Bioventus Class A common stock via RSU vesting and received a new grant of 25,146 RSUs.

Director Mary Kay Ladone exercised restricted stock units and received a new grant of equity in Bioventus Inc.

Director William Hawkins acquired 39,789 shares of Bioventus Class A common stock via RSU vesting and received a new grant of 30,994 RSUs.

Director Philip G. Cowdy acquired 32,282 shares of Bioventus Class A common stock through the vesting of restricted stock units.

Director Pat Beyer acquired 32,282 shares of Bioventus Class A common stock through the vesting of restricted stock units.

Bioventus Inc. reports a correction to a previously filed Form 4, clarifying Director Philip G. Cowdy's beneficial ownership of securities as of April 1, 2021.

Philip G. Cowdy, a Director at Bioventus Inc., filed a Form 4 detailing changes in beneficial ownership, specifically the acceptance of 9,000 Restricted Stock Units.

Bioventus Inc. SVP & CFO Mark Leonard Singleton reported transactions involving Class A Common Stock, including the acquisition of restricted stock units and the sale of shares.

Bioventus Inc. reports insider transactions by SVP & Chief Compliance Officer Katrina J. Church, involving restricted stock units and common stock.

Bioventus Inc. reports insider transactions by SVP & General Counsel Anthony D'Adamio, involving the acquisition of restricted stock units and the disposition of common stock.

Bioventus Inc.'s SVP & CFO, Mark Leonard Singleton, increased his direct ownership of Class A Common Stock following the vesting of restricted stock units and subsequent tax-related sales.

Bioventus Inc.'s SVP & CFO, Mark Leonard Singleton, reported new grants of restricted stock units and stock options, alongside the vesting and tax-related sale of common stock.

Bioventus SVP & Chief Compliance Officer Katrina J. Church reported new equity grants and vesting of existing awards, alongside tax-related stock dispositions.

Bioventus Inc.'s SVP & General Counsel, Anthony D'Adamio, reported recent transactions involving Class A Common Stock, Restricted Stock Units, and Stock Options, primarily related to equity compensation and tax obligations.

Bioventus Inc. CEO Robert E. Claypoole reported significant equity transactions, including RSU vesting, option grants, and stock acquisitions and dispositions.

Bioventus Inc. Director Michelle McMurry-Heath sold 12,000 shares of Class A Common Stock on March 11, 2026, at a weighted average price of $8.7866.

Bioventus Inc.'s SVP & CFO, Mark Leonard Singleton, increased his direct beneficial ownership of Class A Common Stock following the vesting of restricted stock units and a subsequent tax-related disposition.

Bioventus SVP & Chief Compliance Officer Katrina J. Church reported the acquisition and disposition of Class A Common Stock and Restricted Stock Units.

Bioventus Inc.'s SVP & General Counsel, Anthony D'Adamio, reported the acquisition of 12,980 shares and disposition of 6,327 shares of Class A Common Stock related to RSU vesting.

Bioventus Inc.'s President and CEO, Robert E. Claypoole, exercised restricted stock units and subsequently sold shares to cover tax obligations.

Bioventus Inc. Director Guy P. Nohra sold 10,000 shares of Class A Common Stock under a Rule 10b5-1 plan.

Bioventus Inc. Director Michelle McMurry-Heath sold 17,701 shares of Class A Common Stock for a weighted average price of $7.4151.

Bioventus Inc. Director and 10% owner John A. Bartholdson has increased his direct beneficial ownership of Class A Common Stock by 7,575 shares following the vesting of Restricted Stock Units.

John A. Bartholdson, a Director and 10% owner of Bioventus Inc., reported the acquisition of 26,493 shares of Class A Common Stock through RSU vesting and the grant of 32,282 new Restricted Stock Units.

Bioventus Inc. Director and 10% Owner Martin P. Sutter reported the acquisition of 26,493 Class A Common Stock shares through RSU vesting and a new grant of 32,282 Restricted Stock Units.